Median-based incremental cost-effectiveness ratios with censored data

Heejung Bang, Hongwei Zhao

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

Original languageEnglish (US)
JournalJournal of Biopharmaceutical Statistics
DOIs
StateAccepted/In press - Nov 11 2015

Keywords

  • Censoring
  • cost-effectiveness analysis
  • ICER
  • median

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Statistics and Probability

Fingerprint

Dive into the research topics of 'Median-based incremental cost-effectiveness ratios with censored data'. Together they form a unique fingerprint.

Cite this